{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:01:25Z","timestamp":1790190085085,"version":"4.1.0"},"reference-count":23,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:p>Hereditary angioedema (HAE) is defined as a rare genetic disease with recurrent episodes of localized bradykinin-mediated swelling of the deep tissues of the skin, respiratory, and gastrointestinal tracts that can be life threatening. Classification of HAE has evolved over time with\n our further understanding of clinical phenotypes, underlying causes, and available testing. In most cases, HAE is caused by a deficiency of C1-esterase inhibitor (C1-INH) on the Serpin Family G Member 1 (SERPING1) gene, either through decreased amounts of C1-INH protein (C1-INH\u2010HAE,\n type 1) or decreased function of C1-INH (C1-INH\u2010HAE, type 2). HAE with normal C1-INH levels and function are divided into unknown cause or into non\u2010C1-INH\u2010HAE forms, which include known mutational defects in factor XII (called FXII-HAE in the Hereditary Angioedema International\n Working Group consensus), angiopoietin-1, plasminogen, and kininogen 1 genes. It is possible that, after an initial workup, a patient without a family history of HAE could be classified with an acquired form of angioedema (nonhereditary) that may later prove to be HAE due to a de-novo SERPING1\n mutation. Because there are forms of nonhistaminergic (H<jats:sub>1<\/jats:sub>-antihistamine unresponsive) angioedema that appear clinically very similar to HAE, it is essential that the patient undergoes a thorough clinical history and diagnostic evaluation to ensure that he or she is properly diagnosed\n and classified.<\/jats:p>","DOI":"10.2500\/aap.2020.41.200040","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T04:41:14Z","timestamp":1603860074000},"page":"S03-S07","source":"Crossref","is-referenced-by-count":42,"title":["Definition and classification of hereditary angioedema"],"prefix":"10.2500","volume":"41","author":[{"given":"Steven P.","family":"Proper","sequence":"first","affiliation":[{"name":"From the Division of Allergy and Immunology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Lavery","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of Immunology\/Allergy Section, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.6061\/clinics\/2018\/e310","article-title":"Brazilian guidelines for hereditary angioedema management - 2017 update part 1: definition, classification and diagnosis","volume":"73","author":"Giavina-Bianchi","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"B3","first-page":"576","article-title":"Hereditary angioedema and bradykinin-mediated angioedema","volume-title":"Middleton\u2019s allergy: principles and practice","author":"Zuraw","year":"2019"},{"key":"B4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/all.12380","article-title":"Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group","volume":"69","author":"Cicardi","year":"2014","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2013.03.034","article-title":"A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema","volume":"131","author":"Zuraw","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(63)90162-1","article-title":"A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C\u2032 1-esterase","volume":"35","author":"Donaldson","year":"1963","journal-title":"Am J Med"},{"key":"B7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.iac.2017.04.001","article-title":"Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade","volume":"37","author":"Kaplan","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","article-title":"Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema","volume":"6","author":"Lumry","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2500\/aap.2018.39.4151","article-title":"Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks","volume":"39","author":"Baker","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"B10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13223-019-0328-3","article-title":"Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks","volume":"15","author":"Bernstein","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/eci.09.60","article-title":"Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability","volume":"6","author":"Bernstein","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"7","author":"Craig","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2500\/aap.2011.32.3469","article-title":"Update on angioedema: evaluation, diagnosis, and treatment","volume":"32","author":"Bernstein","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"B15","doi-asserted-by":"crossref","first-page":"e0199305","DOI":"10.1371\/journal.pone.0199305","article-title":"Clinical features of patients with homozygous complement C4A or C4B deficiency","volume":"13","author":"Liesmaa","year":"2018","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaip.2014.08.002","article-title":"Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema","volume":"3","author":"Li","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","article-title":"Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema","volume":"141","author":"Bafunno","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/all.13869","article-title":"Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin","volume":"74","author":"Bork","year":"2019","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/all.13270","article-title":"Hereditary angioedema with a mutation in the plasminogen gene","volume":"73","author":"Bork","year":"2018","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.bbrc.2006.03.092","article-title":"Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor","volume":"343","author":"Dewald","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"crossref","first-page":"1142.e9","DOI":"10.1016\/j.amjmed.2013.05.017","article-title":"Antihistamine-resistant angioedema in women with negative family history: estrogens and F12 gene mutations","volume":"126","author":"Bork","year":"2013","journal-title":"Am J Med"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaip.2017.09.025","article-title":"Hereditary angioedema with normal C1 inhibitor and F12 mutations in 42 Brazilian families","volume":"6","author":"Veronez","year":"2018","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/a00106s1\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T04:43:31Z","timestamp":1603860211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2020.41.200040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["1088-5412(20201101)41:6+L.3;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2020.41.200040","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}